Metabolic challengers selecting tumor-persistent cells

Area of Science:

• Oncology
• Cancer Biology
• Tumor Microenvironment Research

Background:

• Anticancer therapy resistance remains a critical challenge in cancer treatment.
• The tumor microenvironment (TME) significantly influences the development of drug resistance.
• Tumor heterogeneity (TH) and epigenetic adaptations are key factors in resistance acquisition.

Purpose of the Study:

• To explore the link between TME metabolic pressures, epigenetics, and tumor-persistent cell (TPC) evolution.
• To understand how TPCs gain resistance advantages through phenotypic and metabolic plasticity.
• To identify novel therapeutic targets for overcoming drug resistance by exploiting TPC vulnerabilities.

Main Methods:

• Analysis of tumor microenvironment components.
• Investigation of epigenetic modifications in tumor cells.
• Characterization of tumor-persistent cell (TPC) plasticity and metabolism.
• Correlation of metabolic pressures with TPC evolution and drug resistance.

Main Results:

• The TME fosters tumor heterogeneity and the emergence of drug-resistant clones.
• Metabolic pressures within the TME promote epigenetic adaptations in tumor cells.
• Tumor-persistent cells (TPCs) exhibit significant phenotypic and metabolic plasticity, conferring chemo- and radio-resistance.

Conclusions:

• Understanding the interplay between TME metabolism, epigenetics, and TPC evolution is crucial.
• Targeting TPC vulnerabilities presents a promising strategy to overcome anticancer therapy resistance.
• Novel therapeutic approaches can be developed by focusing on the metabolic and epigenetic plasticity of TPCs.